Johns Hopkins University

Graham LobelMD, PhD

MD · University of Pennsylvania Perelman School of Medicine

Residency · Osler Internal Medicine Residency, Johns Hopkins University

ORCID 0000-0002-9166-2979

publications

first author

median RCR

0.92

citations

Publications

2024
Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Cancer Immunology Research
2024
Data from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Glutamine availability regulates cDC subsets in tissue
2024
Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Figure S5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2024
Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
2020
Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression
Cell
2019
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
NeurosurgeryRCR 0.9227 citesPMID 30011045

Compiled from public program rosters and open scholarly data (PubMed, OpenAlex, ORCID) with field-normalized impact (NIH iCite RCR). Publication attribution is being actively improved; counts shown are conservative.